MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-14-2022
Calithera Biosciences ROE Ratio 2011-2026 | CALA
Annual ROE Ratio Calithera Biosciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -1373.04 | -88.05 | -63.09 | -43.11 | -18.51 | -76.15 | -45.47 | -21.63 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -18.51 | -1373.04 | -216.13 |
Quarterly ROE Ratio Calithera Biosciences
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 378.27 | 363.26 | 385.39 | 393.9 | -53.91 | -76.12 | -83.31 | -85.99 | -66.01 | -81.26 | -73.3 | -70.34 | -63.09 | -63.22 | -63.85 | -49.32 | -43.11 | -35.02 | -24.19 | -25.22 | -18.51 | -30.29 | -43.37 | -60.67 | -76.15 | -68.31 | -63.59 | -53.73 | -45.47 | -41.04 | -33.86 | -28.45 | -21.63 | 1.12 | 22.28 | 27.75 | 15.94 | 15.94 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 393.9 | -85.99 | 1.62 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Amgen
AMGN
|
89.06 | $ 350.62 | 0.81 % | $ 189 B |  USA |
 |
Heron Therapeutics
HRTX
|
-140.9 | $ 0.8 | 2.35 % | $ 133 M | USA |
 |
Altimmune
ALT
|
-39.17 | $ 3.46 | 3.44 % | $ 305 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 219.42 | -1.11 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
Incyte Corporation
INCY
|
24.9 | $ 90.74 | -0.04 % | $ 17.7 B | USA |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Inovio Pharmaceuticals
INO
|
-115.14 | $ 1.62 | 2.22 % | $ 35.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-115.61 | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
-53.8 | $ 12.92 | 1.41 % | $ 778 M | USA |
 |
Inventiva S.A.
IVA
|
-30.23 | $ 6.13 | 6.06 % | $ 138 M | France |
 |
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
KalVista Pharmaceuticals
KALV
|
-192.31 | $ 16.76 | -1.41 % | $ 832 M | Britain |
 |
Cara Therapeutics
CARA
|
-207.61 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-46.05 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | USA |
 |
Kamada Ltd.
KMDA
|
9.59 | $ 8.23 | -0.24 % | $ 260 M | Israel |
 |
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | USA |
 |
Karyopharm Therapeutics
KPTI
|
41.08 | $ 7.06 | -7.47 % | $ 860 K | USA |
 |
Clovis Oncology
CLVS
|
94.87 | - | -7.23 % | $ 13 M | USA |
 |
Keros Therapeutics
KROS
|
28.7 | $ 11.27 | 2.83 % | $ 419 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
-34.38 | $ 21.23 | 5.26 % | $ 3.49 B | USA |
 |
Longeveron
LGVN
|
-400.07 | $ 0.95 | -3.52 % | $ 16.7 B | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-68.71 | $ 4.3 | 1.3 % | $ 714 M | Canada |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
-36.89 | - | 1.93 % | $ 17.4 M | USA |